Autopsy report · NCT01890798

Drisapersen Duchenne Muscular Dystrophy (DMD) Treatment Protocol

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Rights for the further development of drisapersen have been transferred to Prosensa. Therefore this study has been cancelled before enrollment.”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 3
Sponsor: GlaxoSmithKline
Sponsor type: Industry
Conditions: Muscular Dystrophies
Interventions: Drisapersen
Participants: 0

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.